Asahi Kasei is consistently pursuing its strategy of building a focused, sustainable specialty pharmaceutical platform for immunocompromised and medically complex patient groups
Under the deal, Quiver will receive an undisclosed advance payment and research support
Net sales reached CHF 1,327.8 million, up 2.6% year-on-year in Swiss francs, or 4.3% at constant exchange rates
Expansion at the Oss (NL) site adds capacity and R&D capabilities, supporting the development and manufacturing of ADCs and other novel bioconjugates from First-in-Human to commercialization
Acquisition expands Axol’s portfolio of iPSC-derived retinal organoid and retinal pigment epithelium (RPE) models
This transaction fundamentally strengthens Scinai's CDMO platform
The company’s consolidated revenues rose 17.5% year-on-year to Rs. 2,265 crore
Occlutech develops, manufactures, and commercialises medical devices for congenital heart disease, stroke prevention, and heart failure
The company reported profit before tax of Rs.67 crore, up sharply from Rs.21 crore in the same period last year
The acquisition brings Lilly a novel in vivo cell therapy platform built around engineered circular RNA and proprietary lipid nanoparticles
Subscribe To Our Newsletter & Stay Updated
